Law firm launches probe into Sarepta Therapeutics leadership amid growing scrutiny of biotech executives
Executive summary: Kahn Swick & Foti, LLC announced an investigation into the officers and directors of Sarepta Therapeutics Inc., citing potential securities law violations. The probe raises governance concerns that could affect Sarepta's stock price, increase legal costs, and trigger broader scrutiny of biotech executive accountability.
Who is involved: Sarepta Therapeutics Inc. (Nasdaq: SRPT), its board and executive officers, and the law firm Kahn Swick & Foti, LLC led by former Louisiana Attorney General Charles C. Foti Jr.
Likely next: The law firm will gather evidence and may issue a public report; Sarepta may respond with a special committee or face shareholder demands for independent oversight.
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti Jr., announced on September 4, 2026 that it has opened an investigation into the officers and directors of Sarepta Therapeutics Inc. The move follows a pattern of similar investigations initiated the same day by the same firm into other public companies, suggesting a coordinated effort to examine potential securities law violations. While the announcement does not allege wrongdoing, it signals heightened governance scrutiny that could affect Sarepta’s market perception and prompt further regulatory or shareholder attention.
Timeline
- — Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT (PR Newswire)
- — Sarepta (SRPT) Q2 2026 Earnings Call Transcript (Yahoo Finance)
Analysis — what this means
Sectors affected
- Biotechnology
Historical parallels
- Enron scandal (2001)
- WorldCom accounting scandal (2002)
- Tyco International governance probe (2002)